Abstract
Background: In the present scenario treating Mucormycosis is proving more challenging than COVID-19.

Aim and Objectives: To describe the demographic profile, clinical presentations, and risk factors of COVID-19 associated Mucormycosis.

Materials and Methods: A retrospective cross-sectional study was conducted in 30 patients. Diagnosed cases of Mucormycosis with a history of RTPCR or Rapid antigen positive for COVID infection were included in the study. Patients with a past history of Mucormycosis infection or patients not admitted in the hospital were excluded. The study began after obtaining the Institutional Ethical Committee Approval. The statistical analysis was done to study the Percentage distribution of the risk factors.

Results: About 66.66% patients were male and 33.33% were females. The age of the patients was 52.8 ± 10.3 years. About 76.66% patients were farmers/farm workers. 90% of cases had Maxillary, 25 % Ethmoid and 5% had Sphenoid sinus involved. 23.33% were known diabetic. About 63.33% were having uncontrolled blood glucose level. About 23.33% were known hypertensive. About 66.66% had received steroids, 56.66% required oxygen therapy. 36.66% required Intensive care unit (ICU) and 6.66% required ventilator support during their management of acute COVID infection. None were fully vaccinated for COVID-19.

Conclusion: The males are more susceptible to post-COVID 19 Mucormycosis infection as compared to females. Farmers/farm workers are at an increased risk too. Over use of steroids, uncontrolled blood sugar levels, oxygen therapy, long hospital stay, and ICU procedures and ventilators also contribute to the increased occurrence of post-COVID Mucormycosis. Most important factor that was observed was all the patients suffering from post-COVID Mucormycosis were not vaccinated.